Antidiabetic Flashcards
1
Q
Rx list
A
- insulin
- biguanides (metformin)
- Sulfonureas (glipizide)
- Non-sulfonylurea secretagogues (meglitinides)
- Thiazolidenediones (Pioglitazone)
- GLP-1 Receptor Ags
- Dipeptidyl MORE
2
Q
Insulin replacement
A
Primary Tx Type 1
- recominant
- inject SQ
- new delivery systems, aerosolized nasal
- No liver 1st pass
- Individualize Tx
- REVERSE w/glucose/glucagon
- S.E. : hypoglycemia, dementia old age
3
Q
Insulin types
- ultra short-acting
- rapid acting
- Intermediate acting
- long acting
A
- ultra short-acting = lispro, aspart, glulisine
- rapid acting = standard
- Intermediate acting = NPH
- long acting= Detemir, Glargine
4
Q
Individualized dosing
A
- mixture forms throughout day
- dawn effect = dose at night
- blood glucose
5
Q
Type 2 DM tx
A
*1st line. = wieght exercise
*monotherapy or combo
(Insulin not initially, until progress to beta cell fatigue/degen)
6
Q
Metformin
A
BIGUANIDE 1ST LINE TYPE II, also PRE-DM *only US *can combo w/ oral *sensitizer (enhance effect) insulin *1st line type 2, also prediabetics *activate AMPK (LIVER+ muscle) UP FA oxidation,DOWN gluconeogen, DOWN lipogen, UP glucose uptake *S.E. : NO weight gain (loss maybe), NO hypoglyc, STOP microvascular issues, C/I renal/liver dz/contrast dye, lactic acidosis,
7
Q
Glipizide
A
Sulfonureas SECRETAGOGUE
- UP insulin release from pancreas (same as glucose MOA)
- need functional beta cells
- NO EFFECT insulin sensitivity
- S.E. = 2nd gen not much, hypoglyc, weight gain, C/I renal/liver dz,
- RX-RX = enhance hypoglyc, hyperglyc
8
Q
Repaglinide
A
NON-SUlFONYLUREA SECRETAGOGUES
*Take Right Before Meal
*UP insulin release pancreas, need functional beta
*rapid absorption, shorter action
S.E.: Less risk hypoglyc, weight gain, rx-rx intxn
9
Q
Poiglitazone
A
THIAXOLIDINEDIONES *UP Insulin Sensitivity in target tissues (PPAR-gamma) *NOT hypoglycemic *DOWN liver output glucose *UP glucose use (muscle, fat) *DOWN FFA (adipose) S.E = Fluid retention, weight gain
10
Q
Sitagliptin
A
INCRETIN-BASED DDP-4 INHIBITOR
- prolong GLP-1
- UP glucose mediated insulin
- weight neutral
- S.E.: UP hypoglyc risk w/ insulin secretagogues, cleavage not just to incretins, fatal hepatic failure, long term safety unknown
11
Q
Canagliflozin
A
TYPE II, NOT I
- SGLT-2 inhibitor
- stop renal reabsorption glucose, lower blood glucose
- excretes sodium, facilitates weight loss
- Metab by UDP-GT inducers RX DOWN blood levels
- S.E. = mycotic infxns, recurrent UTIs, Long term safety unknown, ketoacidosis
12
Q
Acarbose
A
Alpha-Glucosidase Blocker
- DOWN GI glucose absorption
- Take w/ meal (post-prandial glycemia)
- S.E. = ab pain, diarrhea, flatulence, alleviated w/ dose titration/continued use, C/I chronic intestinal dz, hypoglyc w/ sulfonylureas/insulin (Tx oral glucose)
13
Q
DM 2 Rx
A
- METFORMIN (biguanide, insuline sensitizer)
- GLIPIZIDE (Sulfonureas)
- REPAGLINIDE (Katp channel secretagogue)
- PIOGLITAZONE (Thiazolidinediones)
- EXANATIDE (GLP-1 Mimetic, incretin)
- CANAGLIFLOZIN (renal SGLT-2 block)
- ACARBOSE (A-Glucosidase block)
14
Q
DM II
Weight gain Rx
A
- GLIPIZIDE: sulfonureas, meglinitides (classic secretagogues)
- PIOGLITAZONE: TZDs (insulin sensitizer)
- REPAGLINIDIDE
15
Q
DM II Rx targets
- METFORMIN (biguanide, insuline sensitizer)
- GLIPIZIDE (Sulfonureas)
- REPAGLINIDE (Katp channel secretagogue)
- PIOGLITAZONE (TZDs)
- EXANATIDE (GLP-1 Mimetic, incretin)
- CANAGLIFLOZIN (SGLT-2 block)
- ACARBOSE (A-Glucosidase block)
A
- METFORMIN = Liver, Muscle
- GLIPIZIDE =
- REPAGLINIDE (Katp channel secretagogue) = Pancreas
- PIOGLITAZONE = Fat, Muscle
- EXANATIDE (GLP-1 Mimetic, incretin)
- CANAGLIFLOZIN = renal
- ACARBOSE = Intestine carbs